Skip to main content
SpringerLink
Log in

Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results

  • Chapter
  • First Online:
Chemotherapy for Leukemia

  • 1345 Accesses

Abstract

CD22 antigen is a B-cell lineage-restricted type I transmembrane protein, a member of Siglec family of cell surface receptors. Expression of CD22 is found in almost all the B cells and most B-lymphoid malignancies including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL).

Inotuzumab ozogamicin (INO) is one of the antibody-drug conjugates (ADCs) that consists of a cytotoxic drug, calicheamicin, attached to a humanized monoclonal anti-CD22 antibody. Based upon clinical trials, INO was shown to be effective for relapsed/refractory ALL as well as B-cell NHL. Single-agent treatment of INO (1.8 mg/m2 once every 3–4 weeks or fractionated weekly, 0.8 mg/m2 on day 1, and 0.5 mg/m2 on day 8 and 15 every 3–4 weeks) provided an objective response rate of 60% in the treatment of relapsed/refractory CD22-positive ALL patients. Combination of INO with rituximab and low-intensive conventional chemotherapy for patients with relapsed/refractory ALL showed better objective response. This review summarizes the clinical efficacy and safety of INO in the treatment of relapsed/refractory ALL, based on currently available data in the literature.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dijoseph J, Armellino D, Boghaert E, Khandke K, Dougher M, Sridharan L, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103:1807–14.

    Article  CAS  PubMed  Google Scholar 

  2. Shor B, Gerber H-P, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2 Pt A):107–16.

    Article  CAS  PubMed  Google Scholar 

  3. Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev. 2009;230:128–43.

    Article  CAS  PubMed  Google Scholar 

  4. Piccaluga PP, Arpinati M, Candoni A, Laterza C, Paolini S, Gazzola A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma. 2011;52:325–7.

    Article  PubMed  Google Scholar 

  5. de Vries JF, Zwaan CM, De Bie M, Voerman JS, den Boer ML, van Dongen JJ, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26:255–64.

    Article  PubMed  Google Scholar 

  6. Gerber HP, Koehn FE, Abraham RT. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep. 2013;30:625–39.

    Article  CAS  PubMed  Google Scholar 

  7. John B, Herrin BR, Raman C, Wang YN, Bobbitt KR, Brody BA, et al. The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction. J Immunol. 2003;170:3534–43.

    Article  CAS  PubMed  Google Scholar 

  8. Raponi S, De Propris MS, Intoppa S, Milani ML, Vitale A, Elia L, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52:1098–107.

    Article  CAS  PubMed  Google Scholar 

  9. Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Investig. 2006;35:93–114.

    Article  CAS  Google Scholar 

  10. Lee MD, Manning JK, Williams DR, Kuck NA, Testa RT, Borders DB. Calicheamicins, a novel family of antitumor antibiotics, 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I. J Antibiot. 1989;42:1070–87.

    Article  CAS  PubMed  Google Scholar 

  11. DiJoseph JF, Dougher MM, Evans DY, Zhou BB, Damle NK. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother Pharmacol. 2011;67:741–9.

    Article  CAS  PubMed  Google Scholar 

  12. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13:47–58.

    Article  CAS  PubMed  Google Scholar 

  13. Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, Bernstein I. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice Linker Bioconjug Chem. 2002;13:40–6.

    Article  CAS  PubMed  Google Scholar 

  14. Advani A, Coiffier B, Czuczman M, Dreyling M, Foran J, Gine E, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28:2085–93.

    Article  CAS  PubMed  Google Scholar 

  15. Ogura M, Tobinai K, Hatake K, Uchida T, Kasai M, Oyama T, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101:1840–5.

    Article  CAS  PubMed  Google Scholar 

  16. Ogura M, Hatake K, Ando K, Tobinai K, Tokushige K, Ono C, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;103:933–8.

    Article  CAS  PubMed  Google Scholar 

  17. Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31:573–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lobo E, Hansen R, Balthasar J. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645–68.

    Article  CAS  PubMed  Google Scholar 

  19. Cao Y, Jusko W. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2014;41:375–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma. Clin Cancer Res. 2006;12:242–9.

    Article  CAS  PubMed  Google Scholar 

  21. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13:403–11.

    Article  CAS  PubMed  Google Scholar 

  22. Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119:2728–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol. 2015;6:253–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Advani A., Stein A., Kantarjian H. A phase II study of weekly inotuzumab ozogamicin (INO) in adult patients with CD22-positive acute lymphoblastic leukemia (ALL) in second or later salvage. In: 56th ASH annual meeting and exposition, 6–9 December, San Francisco, 2014; Abstract 2255.

    Google Scholar 

  25. Jabbour E, O’Brien S, Huang X, Thomas D, Rytting M, Sasaki K, et al. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015;90:193–6.

    Article  CAS  PubMed  Google Scholar 

  26. Sasaki K, Kantarjian HM, O’Brien S, Thomas DA, Ravandi F, Guillermo Garcia-Manero G, et al. Salvage chemotherapy with inotuzumab ozogamicin (INO) combined with mini-Hyper-CVD for adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Blood. 2015;126:3721.

    Google Scholar 

  27. Jabbour E, O’Brien S, Sasaki K, DeThomas DA, Garcia-Manero G, Ravandi F, et al. Frontline inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) for older patients with acute lymphoblastic leukemia (ALL). Blood. 2015;126:83.

    Google Scholar 

  28. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–50.

    Article  CAS  PubMed  Google Scholar 

  29. Kebriaei P, Wilhelm K, Ravandi F, Brandt M, De Lima M, Ciurea S, et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013;13:296–301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Larson R, Sievers E, Stadtmauer E, Lowenberg B, Estey E, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442–52.

    Article  CAS  PubMed  Google Scholar 

  31. Dowell J, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol. 2001;41:1206–14.

    Article  CAS  PubMed  Google Scholar 

  32. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:2310–4.

    Article  CAS  PubMed  Google Scholar 

  33. Lee J, Gooley T, Bensinger W, Schiffman K, Mcdonald G. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 1999;5:306–15.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest Disclosure

Dr. Usui has received research grants and honoraria from CIMIC, Takeda, Eli Lilly Japan, Pfizer, Nippon Boehringer-Ingelheim, Sysmex, Janssen Pharmaceutical, Zenyaku Kogyo, Kyowa Hakko Kirin, Astellas Pharma, Otsuka Pharmaceutical, Celgene, SymBio Pharmaceuticals, Huya Bioscience International, Chugai Pharmaceutical, Bristol-Myers Squibb, and Solasia Pharma.

Author information

Authors and Affiliations

  1. Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University Daisan Hospital, 4-11-1 Izumi-Honcho, Komae, Tokyo, 201-8601, Japan

    Noriko Usui

Authors
  1. Noriko Usui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noriko Usui .

Editor information

Editors and Affiliations

  1. University of Fukui, Fukui, Japan

    Takanori Ueda

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Usui, N. (2017). Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results. In: Ueda, T. (eds) Chemotherapy for Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-10-3332-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-3332-2_7

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-3330-8

  • Online ISBN: 978-981-10-3332-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation